Latest news

Daily Snap - 28. August 2025

Daily Snap - 28. August 2025

Joachim Eeckhout
Wugen secures $115M to fast-track first off-the-shelf CAR-T therapy for T-cell cancers

Wugen secures $115M to fast-track first off-the-shelf CAR-T therapy for T-cell cancers

Eduardo Longoria
Biopharma 2024 slowdown threatens Massachusetts’ leadership role

Biopharma 2024 slowdown threatens Massachusetts’ leadership role

Eduardo Longoria
Daily Snap - 27. August 2025

Daily Snap - 27. August 2025

Joachim Eeckhout
Regeneron's cemdisiran achieves Phase 3 win, confirming siRNA’s potential in treating myasthenia gravis

Regeneron's cemdisiran achieves Phase 3 win, confirming siRNA’s potential in treating myasthenia gravis

Eduardo Longoria
Fosun’s $670 million deal with Sitala keeps pointing towards West’s appetite for Chinese innovation

Fosun’s $670 million deal with Sitala keeps pointing towards West’s appetite for Chinese innovation

Eduardo Longoria
Daily Snap - 25. August 2025

Daily Snap - 25. August 2025

Joachim Eeckhout
AbbVie bets $1.2B on psychedelic breakthrough for depression

AbbVie bets $1.2B on psychedelic breakthrough for depression

Joachim Eeckhout
LB Pharma targets IPO lifeline to fund schizophrenia drug trial

LB Pharma targets IPO lifeline to fund schizophrenia drug trial

Joachim Eeckhout
Daily Snap - 22. August 2025

Daily Snap - 22. August 2025

Joachim Eeckhout
Gilead bets big on in vivo cell therapy with $350M Interius buy

Gilead bets big on in vivo cell therapy with $350M Interius buy

Eduardo Longoria
FDA OKs Ionis' Dawnzera, a new RNA-based drug for rare swelling disorder

FDA OKs Ionis' Dawnzera, a new RNA-based drug for rare swelling disorder

Eduardo Longoria
FirstBack
1314151617181920
Next Last